Recordati

Moderna offloads late-stage rare disease drug for $50M upfront

Moderna has out-licensed the drug candidate to Recordati, accepting $50 million upfront for an asset that could deliver registrational data this year.

Nick Paul Taylor Jan 30, 2026 4:14am

Pfizer snags McKinsey partner to lead M&A hunt—Chutes & Ladders

Aug 27, 2021 9:30am

Ex-Novartis, Chiasma leader joins Recordati Rare Diseases as CMO

Aug 25, 2021 12:37pm